华润医药(03320)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03320 华润医药

未开盘 02-01 16:08:35

6.070

+0.170

+2.88%

最高6.070	最低5.880	成交量787.86万
今开5.910	昨收5.900	日振幅3.22%
总市值381.35亿	流通市值381.35亿	总股本62.83亿
成交额4,731万	换手率0.13%	流通股本62.83亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03320","market":"HK","secType":"STK","nameCN":"华润医药","latestPrice":6.07,"timestamp":1675238915015,"preClose":5.9,"halted":0,"volume":7878560,"delay":0,"floatShares":6282510461,"shares":6282510461,"eps":0.599901,"marketStatus":"未开盘","marketStatusCode":0,"change":0.17,"latestTime":"02-01 16:08:35","open":5.91,"high":6.07,"low":5.88,"amount":47310164,"amplitude":0.032203,"askPrice":6.07,"askSize":254500,"bidPrice":6.05,"bidSize":74500,"shortable":3,"etf":0,"ttmEps":0.693326,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1675301400000},"adr":0,"listingDate":1477584000000,"adjPreClose":5.9,"dividendRate":0.024712,"volumeRatio":1.1485551174155548,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03320","defaultTab":"news","newsList":[{"id":"2307754668","title":"华润医药(03320.HK)公布东阿阿胶截至2022年12月31日止年度业绩预告","url":"https://stock-news.laohu8.com/highlight/detail?id=2307754668","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2307754668?lang=zh_CN&edition=full","pubTime":"2023-01-31 09:10","pubTimestamp":1675127430,"startTime":"0","endTime":"0","summary":"截至2023年1月30日收盘，华润医药报收于5.94港元，下跌4.5%，换手率0.12%，成交量774.69万股，成交额4659.47万港元。投行对该股的评级以买入为主，近90天内共有1家投行给出买入评级，近90天的目标均价为8.5港元。招商证券(香港)最新一份研报给予华润医药买入评级，目标价8.5港元。机构评级详情见下表：华润医药港股市值390.77亿港元，在化学制药行业中排名第4。主要指标见下表：以上内容由证券之星根据公开信息整理，与本站立场无关。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://stock.stockstar.com/RB2023013100001772.shtml","is_publish_highlight":false},{"id":"2307779653","title":"【公司盈喜】华润医药(03320)：东阿阿胶预计去年净利润约7.60-8.10亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2307779653","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2307779653?lang=zh_CN&edition=full","pubTime":"2023-01-31 08:23","pubTimestamp":1675124614,"startTime":"0","endTime":"0","summary":"华润医药(03320)公布，2023年1月30日，附属公司东阿阿胶(000423)公布业绩预告，据此，其公告截至2022年12月31日止年度归属于东阿阿胶股东的净利润预计约7.60-8.10亿元人民币(下同)(上年同期：净盈利约4.4亿元)、扣除非经常性损益后的净利润预计约6.86-7.36亿元(上年同期：净盈利约3.52亿元)、基本每股收益预计约1.18元-1.26元╱股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=4f712b01a0bbfbadc0f8b710f25e8e1c","is_publish_highlight":false},{"id":"2307550617","title":"华润医药：东阿阿胶2022年归母净利预计约7.6亿-8.1亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2307550617","media":"界面新闻","top":-1,"share":"https://www.laohu8.com/m/news/2307550617?lang=zh_CN&edition=full","pubTime":"2023-01-31 07:34","pubTimestamp":1675121672,"startTime":"0","endTime":"0","summary":"2023年1月31日,华润医药公告东阿阿胶截至2022年12月31日止年度业绩预告。东阿阿胶的股份于深圳证券交易所上市。截至本公告日期，东阿阿胶由华润医药集团有限公司直接持有8.86%股权，通过公司非全资附属公司华润东阿阿胶有限公司持有约23.14%，集团实际控制东阿阿胶约21.96%并入账为公司的附属公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023013107371184091c4e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023013107371184091c4e&s=b","is_publish_highlight":false},{"id":"2306787233","title":"机构：港股牛市格局确立 下周预计上冲23000点","url":"https://stock-news.laohu8.com/highlight/detail?id=2306787233","media":"兴业证券","top":-1,"share":"https://www.laohu8.com/m/news/2306787233?lang=zh_CN&edition=full","pubTime":"2023-01-28 15:14","pubTimestamp":1674890068,"startTime":"0","endTime":"0","summary":"大市回顾1月27日，港股震荡盘升，早间恒指高开48点，短暂扩大至134点高见22700点，之后震荡回落，最多跌83点低见22483，午后回稳，收盘恒指涨升122点或0.54%，报22688；国企指数升66点或0.87%；恒生科技指数升49点或1.04%。成交总额972.5亿港元。港股通将在下周一(1月30日)恢复。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://hk.eastmoney.com/news/1797,202301282620176512.html","is_publish_highlight":false},{"id":"2306842576","title":"富瑞：维持华润医药(03320)“买入”评级 目标价升至7港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2306842576","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2306842576?lang=zh_CN&edition=full","pubTime":"2023-01-27 15:09","pubTimestamp":1674803353,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，富瑞发布研究报告称，维持华润医药(03320)“买入”评级，目标价由6.1港元上调至7港元。公司旗下华润生物医药(CR Biopharm)刚在B轮融资筹集8900万美元，并认为华润双鹤(600062.SH)、江中药业(600750.SH)、以及博雅生物(300294.SZ)均会在今年开始疫情后复苏、并推动其第三批带量采购(VBP)和药品集中采购(GPO)，同时东阿阿胶(000423.SZ)及华润三九(000999.SZ)将继续保持其增长势头。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/866867.html","is_publish_highlight":false},{"id":"2306423447","title":"《大行报告》富瑞上调华润医药(03320.HK)目标价至7元  评级“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2306423447","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2306423447?lang=zh_CN&edition=full","pubTime":"2023-01-27 14:09","pubTimestamp":1674799740,"startTime":"0","endTime":"0","summary":"富瑞发表报告指，华润医药旗下华润生物医药刚在B轮融资筹集8,900万美元，并认为华润双鹤、江中药业、以及博雅生物均会在今年开始疫情后复苏、并推动其第三批带量采购和药品集中采购，同时东阿阿胶及华润三九将继续保持其增长势头。该行将华润医药目标价由6.1元上调至7元，相当于今年每股盈测8.8倍，维持其评级为“买入”。(港股报价延迟最少十五分钟。沽空资料截至 2023-01-27 12:25。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190604131519775_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190604131519775_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1241230/latest-news/HK6","is_publish_highlight":false},{"id":"2304708046","title":"华润医药：华润三九预计2022年度净利润约23.65亿至25.7亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2304708046","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2304708046?lang=zh_CN&edition=full","pubTime":"2023-01-20 08:46","pubTimestamp":1674175560,"startTime":"0","endTime":"0","summary":"　　华润医药发布华润三九截至2022年12月31日止年度业绩预告，归属于华润三九股东的净利润预计约23.65亿元至25.7亿元、扣除非经常性损益后的归属于华润三九股东的净利润预计约21.5亿元至23.2亿元、基本每股收益预计约2.4元╱股至约2.61元╱股。　　本次业绩变动的原因是由于华润三九顺应行业发展趋势，积极应对市场变化，持续进行创新升级，不断强化品牌建设，优化产品结构，推动盈利能力提升。炒股开户享福利，入金抽188元红包，100%中奖！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-01-20/doc-imyauwyt0090448.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-01-20/doc-imyauwyt0090448.shtml","is_publish_highlight":false},{"id":"2304786676","title":"华润医药(03320)：华润三九预计2022年度净利润约23.65亿-25.7亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2304786676","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2304786676?lang=zh_CN&edition=full","pubTime":"2023-01-20 06:17","pubTimestamp":1674166678,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润医药 发布华润三九截至2022年12月31日止年度业绩预告，归属于华润三九股东的净利润预计约23.65亿元至25.7亿元、扣除非经常性损益后的归属于华润三九股东的净利润预计约21.5亿元至23.2亿元、基本每股收益预计约2.4元╱股至约2.61元╱股。本次业绩变动的原因是由于华润三九顺应行业发展趋势，积极应对市场变化，持续进行创新升级，不断强化品牌建设，优化产品结构，推动盈利能力提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/865270.html","is_publish_highlight":false},{"id":"2303184743","title":"南向资金1月12日净卖出华润医药383.05万股 连续7日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2303184743","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2303184743?lang=zh_CN&edition=full","pubTime":"2023-01-13 09:30","pubTimestamp":1673573455,"startTime":"0","endTime":"0","summary":"1月12日，南向资金减持华润医药383.05万股连续7日减持。截止当日收盘，港股通共持有华润医药18682.92万股，占流通股2.96%。华润医药近5个交易日下跌6.07%，港股通累计减持1283.50万股；近20个交易日下跌13.15%，港股通累计减持1038.15万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202301130934338060eaf1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202301130934338060eaf1&s=b","is_publish_highlight":false},{"id":"2302743871","title":"南向资金1月6日净卖出华润医药351.00万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2302743871","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2302743871?lang=zh_CN&edition=full","pubTime":"2023-01-09 09:31","pubTimestamp":1673227862,"startTime":"0","endTime":"0","summary":"1月6日，南向资金减持华润医药351.00万股连续3日减持。截止当日收盘，港股通共持有华润医药19615.42万股，占流通股3.12%。港股通减持金额前五个股分别为建设银行、安踏体育、碧桂园、兖矿能源、万科企业。华润医药近5个交易日下跌2.80%，港股通累计减持494.15万股；近20个交易日下跌1.26%，港股通累计减持352.75万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023010909360582af801e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023010909360582af801e&s=b","is_publish_highlight":false},{"id":"2300481104","title":"华润医药(03320.HK)发布公告，有关建议收购昆药集团股份有限公司(昆药)的权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2300481104","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2300481104?lang=zh_CN&edition=full","pubTime":"2023-01-03 09:20","pubTimestamp":1672708828,"startTime":"0","endTime":"0","summary":"截至2022年12月30日收盘，华润医药报收于6.32元，下跌1.86%，换手率0.08%，成交量500.98万股，成交额3186.87万元。招商证券(香港)最新一份研报给予华润医药买入评级，目标价8.5。机构评级详情见下表：华润医药港股市值397.05亿港元，在化学制药行业中排名第4。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://stock.stockstar.com/RB2023010300001009.shtml","is_publish_highlight":false},{"id":"2295990914","title":"华润医药(03320.HK)与华润租赁订立2023/2024年华润租赁战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2295990914","media":"金融界网站","top":-1,"share":"https://www.laohu8.com/m/news/2295990914?lang=zh_CN&edition=full","pubTime":"2022-12-30 21:42","pubTimestamp":1672407729,"startTime":"0","endTime":"0","summary":"格隆汇12月30日丨华润医药(03320.HK)公布，于2022年12月30日，公司与华润租赁订立2023/2024年华润租赁战略合作协议，期限于2023年1月1日开始并于2024年12月31日终止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://hk.jrj.com.cn/2022/12/30214237251230.shtml","is_publish_highlight":false},{"id":"2295905244","title":"华润医药(03320)与华润银行及华润信托分别订立战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2295905244","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2295905244?lang=zh_CN&edition=full","pubTime":"2022-12-30 20:59","pubTimestamp":1672405155,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润医药(03320)公布，于2022年12月30日，公司与华润银行及华润信托分别订立2023/2024年华润银行战略合作协议及2023/2024年华润信托战略合作协议，期限于2023年1月1日开始并于2024年12月31日终止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/855546.html","is_publish_highlight":false},{"id":"2293556316","title":"华润医药(03320.HK)：收购昆药集团交易获国资委原则上同意","url":"https://stock-news.laohu8.com/highlight/detail?id=2293556316","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2293556316?lang=zh_CN&edition=full","pubTime":"2022-12-23 08:31","pubTimestamp":1671755460,"startTime":"0","endTime":"0","summary":"华润医药(03320.HK) 公布，有关建议收购昆药集团的权益，国资委原则上同意华润三九通过受让华立集团所持昆药集团333.55万股股份、受让华立医药集团所持昆药集团2.09亿股股份等方式取得昆药集团控股权的整体方案。华润三九于股份转让协议项下的建议收购事项须达成若干先决条件后方可作实，包括华润三九股东大会审议通过是次建议收购事项方案。截至目前，建议收购事项尚未完成。(jl/k)(港股报价延迟最少十五分钟。沽空资料截至 2022-12-22 16:25。)","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20210624132643819_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20210624132643819_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1234900/latest-news/HK6","is_publish_highlight":false},{"id":"2287215695","title":"港股概念追踪 | 精准防控持续推进 抗原检测受关注 医药诊疗、零售药店等景气度有望快速恢复(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2287215695","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2287215695?lang=zh_CN&edition=full","pubTime":"2022-11-29 15:22","pubTimestamp":1669706571,"startTime":"0","endTime":"0","summary":"同月，国家医保局近日发布通知，各省份可按程序将新冠病毒抗原检测试剂临时纳入各省医保目录。根据新冠肺炎疫情风险区划定及管控方案，出现本土疫情辖区内的零售药店进行分级管控。中、高风险区域内零售药店应当暂停销售《目录》药品 ，直至解除风险管理。9月份，全国零售药店规模同比增长1.0％。同时，在新冠疫情精准防控持续推进的情况下，建议关注检测领域的抗原检测赛道。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/838765.html","is_publish_highlight":false},{"id":"2286809365","title":"华润医药(03320.HK)附属华润双鹤造影剂获药品注册证书  膺中国地区独家代理","url":"https://stock-news.laohu8.com/highlight/detail?id=2286809365","media":"AAFN","top":-1,"share":"https://www.laohu8.com/m/news/2286809365?lang=zh_CN&edition=full","pubTime":"2022-11-25 12:56","pubTimestamp":1669352165,"startTime":"0","endTime":"0","summary":"华润医药  公布，集团旗下华润双鹤作为境内代理人申报的八氟丙烷脂质微球注射液，获得国家药品监督管理局颁发的《药品注册证书》，成为该药品在中国地区独家代理。该药品为造影剂，由美国兰索斯医学影像公司研制。该药品于2000年在加拿大批准上市，2001年在美国批准上市，2006年在欧盟批准上市，目前已经在10余个国家和地区获批上市，本次为同类产品在中国内地首次获准上市。根据兰索斯2021年报显示，其“DEFINITY”2021年全球销售额为2.33亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1229078&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_publish_highlight":false},{"id":"2285011949","title":"【鹏格斯投资心得】反转中的AH医药板块 – 华润医药（03320）浅析","url":"https://stock-news.laohu8.com/highlight/detail?id=2285011949","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2285011949?lang=zh_CN&edition=full","pubTime":"2022-11-21 13:39","pubTimestamp":1669009172,"startTime":"0","endTime":"0","summary":"华润医药是国内最大中药龙头，也是背靠华润也是国内三大医药分销商之一。这些企业在2022年优秀的业绩和中药内部题材轮动是支撑华润医药股价上行的核心催化剂。分销业务简评分销业务由于隔离政策和流动性限制，中国的医院处方药销售额在 1H22 同比下降 8%。处方药销售额同比下降 14%，而 2022 年第一季度同比下降 1%。C 基金暂持有相关华润医药个股的长/短仓。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=f45327fb267061e5d4bb8c32fb22338c","is_publish_highlight":false},{"id":"2284724025","title":"华润医药(03320.HK)旗下天东制药入选山东省首批科技小巨人企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2284724025","media":"AAFN","top":-1,"share":"https://www.laohu8.com/m/news/2284724025?lang=zh_CN&edition=full","pubTime":"2022-11-18 18:08","pubTimestamp":1668766081,"startTime":"0","endTime":"0","summary":"华润医药  宣布，集团旗下东营天东制药入选山东省首批科技小巨人企业名单。「科技小巨人企业评选」是在山东省科技厅的指导下，由山东省科学院情报研究所、山东省创新发展研究院针对山东省有效期内的2万家高新技术企业，从创新投入、创新产出、创新绩效等角度，对企业创新能力进行研究测算，遴选各细分领域中成长速度快、发展潜力大的科技小巨人企业，以进一步完善科技企业梯次培育体系，充分发挥其在推动经济高质量发展中的引领支撑作用。(ad/u)~阿思达克财经新闻网址: www.aastocks.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1227575&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_publish_highlight":false}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0117},{"period":"1month","weight":-0.0396},{"period":"3month","weight":-0.0033},{"period":"6month","weight":0.3253},{"period":"1year","weight":0.6549},{"period":"ytd","weight":-0.0396}],"websiteUrl":"http://www.crpharm.com","compareEarnings":[{"period":"1week","weight":0.0012},{"period":"1month","weight":0.1158},{"period":"3month","weight":0.4389},{"period":"6month","weight":0.0926},{"period":"1year","weight":-0.0727},{"period":"ytd","weight":0.1158}],"name":"华润医药","description":"华润医药集团有限公司是一家香港投资控股公司。该公司及其子公司主要从事医药及其他保健品的研发、制造、分销及零售业务。该公司主要通过三大分部运营。制药分部研发、制造及销售医药及营养保健品。医药分销分部向医药制造商及配药商提供分销解决方案，如医院及其他医疗机构、分销商及零售药店。药品零售分部在中国及香港经营零售药店。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.00066},{"month":2,"riseRate":0.714286,"avgChangeRate":0.037426},{"month":3,"riseRate":0.666667,"avgChangeRate":-0.016816},{"month":4,"riseRate":0.833333,"avgChangeRate":0.026663},{"month":5,"riseRate":0.5,"avgChangeRate":-0.008544},{"month":6,"riseRate":0.5,"avgChangeRate":0.020341},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.04395},{"month":8,"riseRate":0.5,"avgChangeRate":0.032668},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.048781},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.021521},{"month":11,"riseRate":0.428571,"avgChangeRate":0.025921},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.010761}],"exchange":"SEHK","nameEN":"CHINARES PHARMA","compareStock":{"symbol":"HSI","name":"恒生指数"}},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.11.11","shortVersion":"4.11.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华润医药(03320)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华润医药(03320)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华润医药,03320,华润医药股票,华润医药股票老虎,华润医药股票老虎国际,华润医药行情,华润医药股票行情,华润医药股价,华润医药股市,华润医药股票价格,华润医药股票交易,华润医药股票购买,华润医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华润医药(03320)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华润医药(03320)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}